Flow cytometric analysis of human peripheral blood leukocytes labelling Human CD319 antibody at 1/200 dilution (1 μg) / (Right panel) compared with a Mouse IgG2b, κ Isotype Control / (Left panel). Goat Anti-Mouse IgG Alexa Fluor® 647 was used as the secondary antibody. Then cells were stained with CD3 - Brilliant Violet 421™ Antibody separately.
Mouse Anti-Human CD319 Antibody (S-3010)
Mouse Anti-Human CD319 Antibody (S-3010)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD319 |
| Synonyms | SLAM family member 7; CD2 subset 1; CD2-like receptor-activating cytotoxic cells (CRACC); Membrane protein FOAP-12; Novel Ly9; Protein 19A; CS1; SLAMF7 |
| Location | Membrane |
| Accession | Q9NQ25 |
| Clone Number | S-3010 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2b,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | human peripheral blood leukocytes |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:200 | Hu |
Background
CD319, also termed SLAMF7 or CS1, is a 66 kDa self-ligating type-I trans-membrane glycoprotein of the CD2/SLAM immunoglobulin superfamily that is constitutively expressed on NK cells, activated B cells, monocytes and, at very high levels, on multiple-myeloma cells; its cytoplasmic tail contains ITSM sequences that, depending on the simultaneous presence or absence of the adaptor proteins EAT-2 and SAP, can switch between activating (via PI3K-PLCγ-ERK) and inhibitory signaling, thereby modulating NK-cell cytotoxicity, B-cell proliferation, macrophage cytokine release and antibody-dependent myeloma killing, making it both an immunomodulatory receptor and the therapeutic target of the FDA-approved monoclonal antibody elotuzumab.
Picture
Picture
FC
